Innoviva Gets FDA Approval for Gonorrhea Drug
By Katherine Hamilton
Innoviva received approval from the Food and Drug Administration for Nuzolvence, a treatment of gonorrhea.
Nuzolvence has been approved as a single-dose oral medication to treat uncomplicated urogenital gonorrhea in patients 12 years and older, the biopharmaceutical company said Friday.
Innoviva plans to commercialize the drug in the second half of 2026, either in collaboration with a commercialization partner or independently.
The approval comes after Nuzolvence demonstrated non-inferiority compared with other treatments in a phase 3 trial of 930 patients.
Gonorrhea is the second-most common sexually transmitted bacterial infection in the world, with more than 82 million new cases a year, according to the company. Without timely treatment, it can lead to serious and potentially permanent health complications.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 12, 2025 17:29 ET (22:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States